Fulgent Acquires Bako and StrataDx for $55.5 Million
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 22 2025
0mins
Should l Buy FLGT?
Source: Businesswire
- Acquisition Announcement: Fulgent Genetics has announced a definitive agreement to acquire selected assets of Bako Diagnostics and StrataDx for approximately $55.5 million, which is expected to close in the first half of 2026, marking a significant expansion in its laboratory services platform in the pathology testing market.
- Market Expansion: This acquisition will enable Fulgent to add new products and services, further expanding its national client base and sales team, which is anticipated to enhance the company's competitiveness in the rapidly growing medical testing market.
- Technology Integration: Fulgent plans to leverage its foundational technology platform alongside the expertise from Bako and StrataDx to improve service efficiency and quality, driving continued momentum in its laboratory services business, with expectations of achieving double-digit organic growth.
- Strategic Fit: CEO Ming Hsieh emphasized the strategic significance of the acquisition, stating that by integrating advanced technology and specialized expertise, Fulgent aims to enhance client experience and accelerate market penetration, thereby solidifying its leadership position in the industry.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy FLGT?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on FLGT
Wall Street analysts forecast FLGT stock price to rise
2 Analyst Rating
1 Buy
1 Hold
0 Sell
Moderate Buy
Current: 14.880
Low
30.00
Averages
32.50
High
35.00
Current: 14.880
Low
30.00
Averages
32.50
High
35.00
About FLGT
Fulgent Genetics, Inc. is a technology-based company with a laboratory services business and a therapeutic development business. Its laboratory services business includes technical laboratory and testing services and professional interpretation of laboratory results by licensed physicians. Its therapeutic development business is focused on developing drug candidates for treating a range of cancers using a novel nanoencapsulation and targeted therapy platform designed to improve the therapeutic window and pharmacokinetic profile of new and existing cancer drugs. Its testing services include comprehensive anatomic pathology testing services, including gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology, and precision diagnostics testing services, including next-generation sequencing (NGS), tests for biopharma research and clinical tests for rare disease, hereditary cancer, reproductive health, and many other diseases.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Pomerantz Investigates Fulgent Genetics for Securities Fraud
- Securities Fraud Investigation: Pomerantz LLP is investigating Fulgent Genetics for potential securities fraud or unlawful business practices by its officers, which could lead to significant losses for investors.
- Lowered Guidance: On February 27, 2026, Fulgent reported lower-than-expected guidance for 2026, primarily due to its largest customer moving significant work in-house, indicating market pressures on the company.
- Stock Price Plunge: Following the disappointing guidance, Fulgent's stock price fell by $9.43, or 38.09%, closing at $15.33 per share on February 27, 2026, reflecting investor concerns about the company's future outlook.
- Potential Legal Consequences: Pomerantz LLP, a prominent securities litigation firm, may provide legal support to affected investors, potentially exacerbating Fulgent's legal and financial risks.
See More
Fulgent Genetics Under Investigation for Securities Fraud
- Securities Fraud Investigation: Pomerantz LLP is investigating whether Fulgent Genetics has engaged in securities fraud or other unlawful business practices, which could undermine investor confidence and lead to further declines in stock price.
- Poor Financial Performance: Fulgent's financial results released on February 27, 2026, revealed lower-than-expected performance for Q4 and the full year 2025, particularly with disappointing guidance for 2026 due to its largest customer moving significant work in-house.
- Stock Price Plunge: Following this news, Fulgent's stock price fell by $9.43, or 38.09%, closing at $15.33 per share on February 27, 2026, reflecting the market's pessimism regarding the company's future prospects.
- Potential Legal Consequences: Should the investigation confirm misconduct by Fulgent and its executives, the company may face class action lawsuits, further damaging its reputation and impacting future financing capabilities.
See More
Fulgent Genetics Under Investigation for Potential Investor Claims
- Earnings Miss: Fulgent Genetics reported approximately $322.7 million in full-year 2025 revenue, slightly below the updated guidance, indicating pressure on the company's market position.
- Customer Concentration Risk: The transition of Fulgent's largest customer to in-house testing led to a decline in fourth-quarter revenue, with this customer accounting for 22% of total revenue in 2025, highlighting the risks associated with reliance on a single client.
- Uncertain Outlook: The anticipated significant impact on revenue in the first half of 2026 due to customer transition has shaken investor confidence in future performance, resulting in a decline in stock price.
- Legal Investigation Initiated: Johnson Fistel is investigating whether Fulgent complied with federal securities laws, encouraging investors who suffered losses from Fulgent stock to join the investigation for potential recovery.
See More
FULGENT GENETICS INC: UBS Lowers Price Target from $35 to $22
Company Overview: Fulgen Genetics is a company focused on genetic testing and related services.
Stock Price Change: The target price for Fulgen Genetics has been reduced from $35 to $22.
See More
Fulgent Genetics Q4 2025 Earnings Call Insights
- Revenue Growth: Fulgent Genetics reported fourth-quarter revenue of $83.3 million, a 9% year-over-year increase, with full-year revenue reaching $322.7 million, up 14%, indicating ongoing progress in laboratory services and therapeutic development.
- Technology Investment Returns: The launch of the proprietary imaging management system Eziopath, along with the integration of RNA whole genome sequencing and ultra-rapid sequencing, is expected to drive revenue and margin improvements, further solidifying the company's leadership in digital pathology and AI.
- Customer Concentration Risk: The transition of the largest customer to in-house processing is anticipated to result in revenue loss, but management expects to offset this through acquisitions of Bako and StrataDx, projecting additional revenue of $50 to $55 million from these deals.
- Future Outlook: Projected revenue for 2026 is $350 million, representing an 8.5% year-over-year growth, and despite facing margin pressure, management maintains strong confidence in their technology platform and product innovations, which are expected to support long-term revenue growth and improved operating leverage.
See More
First Horizon and Oracle Options Show High Trading Volume
- First Horizon Options Activity: First Horizon Corp (FHN) has seen an options volume of 41,552 contracts today, representing approximately 4.2 million underlying shares, which accounts for 62.7% of its average daily trading volume of 6.6 million shares over the past month, indicating a significant increase in market interest.
- High Call Option Volume: The $26 strike call option for FHN has traded 20,162 contracts today, equating to about 2.0 million shares, suggesting that investors are increasingly optimistic about future price increases, which could influence market sentiment.
- Oracle Options Activity: Oracle Corp (ORCL) has recorded an options volume of 188,976 contracts today, representing approximately 18.9 million underlying shares, which is 62.3% of its average daily trading volume of 30.3 million shares over the past month, reflecting strong investor interest in the company.
- High Put Option Volume: The $116 strike put option for ORCL has seen 13,635 contracts traded today, representing around 1.4 million shares, indicating market concerns about potential future price declines, which may affect investor decision-making.
See More
Pomerantz Investigates Fulgent Genetics for Securities Fraud
- Securities Fraud Investigation: Pomerantz LLP is investigating Fulgent Genetics for potential securities fraud or unlawful business practices by its officers, which could lead to significant losses for investors.
- Lowered Guidance: On February 27, 2026, Fulgent reported lower-than-expected guidance for 2026, primarily due to its largest customer moving significant work in-house, indicating market pressures on the company.
- Stock Price Plunge: Following the disappointing guidance, Fulgent's stock price fell by $9.43, or 38.09%, closing at $15.33 per share on February 27, 2026, reflecting investor concerns about the company's future outlook.
- Potential Legal Consequences: Pomerantz LLP, a prominent securities litigation firm, may provide legal support to affected investors, potentially exacerbating Fulgent's legal and financial risks.
See More
Fulgent Genetics Under Investigation for Securities Fraud
- Securities Fraud Investigation: Pomerantz LLP is investigating whether Fulgent Genetics has engaged in securities fraud or other unlawful business practices, which could undermine investor confidence and lead to further declines in stock price.
- Poor Financial Performance: Fulgent's financial results released on February 27, 2026, revealed lower-than-expected performance for Q4 and the full year 2025, particularly with disappointing guidance for 2026 due to its largest customer moving significant work in-house.
- Stock Price Plunge: Following this news, Fulgent's stock price fell by $9.43, or 38.09%, closing at $15.33 per share on February 27, 2026, reflecting the market's pessimism regarding the company's future prospects.
- Potential Legal Consequences: Should the investigation confirm misconduct by Fulgent and its executives, the company may face class action lawsuits, further damaging its reputation and impacting future financing capabilities.
See More
Fulgent Genetics Under Investigation for Potential Investor Claims
- Earnings Miss: Fulgent Genetics reported approximately $322.7 million in full-year 2025 revenue, slightly below the updated guidance, indicating pressure on the company's market position.
- Customer Concentration Risk: The transition of Fulgent's largest customer to in-house testing led to a decline in fourth-quarter revenue, with this customer accounting for 22% of total revenue in 2025, highlighting the risks associated with reliance on a single client.
- Uncertain Outlook: The anticipated significant impact on revenue in the first half of 2026 due to customer transition has shaken investor confidence in future performance, resulting in a decline in stock price.
- Legal Investigation Initiated: Johnson Fistel is investigating whether Fulgent complied with federal securities laws, encouraging investors who suffered losses from Fulgent stock to join the investigation for potential recovery.
See More
FULGENT GENETICS INC: UBS Lowers Price Target from $35 to $22
Company Overview: Fulgen Genetics is a company focused on genetic testing and related services.
Stock Price Change: The target price for Fulgen Genetics has been reduced from $35 to $22.
See More
Fulgent Genetics Q4 2025 Earnings Call Insights
- Revenue Growth: Fulgent Genetics reported fourth-quarter revenue of $83.3 million, a 9% year-over-year increase, with full-year revenue reaching $322.7 million, up 14%, indicating ongoing progress in laboratory services and therapeutic development.
- Technology Investment Returns: The launch of the proprietary imaging management system Eziopath, along with the integration of RNA whole genome sequencing and ultra-rapid sequencing, is expected to drive revenue and margin improvements, further solidifying the company's leadership in digital pathology and AI.
- Customer Concentration Risk: The transition of the largest customer to in-house processing is anticipated to result in revenue loss, but management expects to offset this through acquisitions of Bako and StrataDx, projecting additional revenue of $50 to $55 million from these deals.
- Future Outlook: Projected revenue for 2026 is $350 million, representing an 8.5% year-over-year growth, and despite facing margin pressure, management maintains strong confidence in their technology platform and product innovations, which are expected to support long-term revenue growth and improved operating leverage.
See More
First Horizon and Oracle Options Show High Trading Volume
- First Horizon Options Activity: First Horizon Corp (FHN) has seen an options volume of 41,552 contracts today, representing approximately 4.2 million underlying shares, which accounts for 62.7% of its average daily trading volume of 6.6 million shares over the past month, indicating a significant increase in market interest.
- High Call Option Volume: The $26 strike call option for FHN has traded 20,162 contracts today, equating to about 2.0 million shares, suggesting that investors are increasingly optimistic about future price increases, which could influence market sentiment.
- Oracle Options Activity: Oracle Corp (ORCL) has recorded an options volume of 188,976 contracts today, representing approximately 18.9 million underlying shares, which is 62.3% of its average daily trading volume of 30.3 million shares over the past month, reflecting strong investor interest in the company.
- High Put Option Volume: The $116 strike put option for ORCL has seen 13,635 contracts traded today, representing around 1.4 million shares, indicating market concerns about potential future price declines, which may affect investor decision-making.
See More
